Rapid regression of retinal hemorrhage and neovascularization in a case of familial exudative vitreoretinopathy treated with intravitreal bevacizumab.
OBJECTIVE
To report a case of familial exudative vitreoretinopathy (FEVR) rapidly resolved by intravitreal injection of bevacizumab.


METHODS
A 36-year-old woman complained about floaters and visual field defect. Funduscopic examinations revealed retinal vessel anastomosis located between the equator and ora serrata in both eyes. The right eye was accompanied with slight vitreous hemorrhage. Since the patient declined retinal cryopexy for cosmetic reasons, intravitreal bevacizumab injections (1.25 mg/0.05 ml) were performed in both eyes.


RESULTS
Treatment resulted in the rapid regression and the accelerated fibrosis of neovascular tissues. At 4-month follow-up in the right eye and 1-month follow-up in the left, no signs of systemic or ocular complications were detected.


CONCLUSIONS
Intravitreal injection of bevacizumab may be considered as an alternative method in treating FEVR.
Tagami
Mizuki
M
Department of Surgery, Division of Ophthalmology, Kobe University Graduate School of Medicine, 7-5-2 Kusunoki-cho, Chuo-ku, Kobe, 650-0017, Japan.
Kusuhara
Sentaro
S
Honda
Shigeru
S
Tsukahara
Yasutomo
Y
Negi
Akira
A
D000328:Adult; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D005122:Exudates and Transudates / Q000378:metabolism; D005128:Eye Diseases / Q000150:complications / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism; D005260:Female; D005654:Fundus Oculi; D006801:Humans; D007267:Injections; D009389:Neovascularization, Pathologic / Q000209:etiology* / Q000473:pathology; D012074:Remission Induction; D012164:Retinal Diseases / Q000150:complications / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism; D012166:Retinal Hemorrhage / Q000209:etiology* / Q000473:pathology; D012171:Retinal Vessels; D013997:Time Factors; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014822:Vitreous Body
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab
Fortschr Ophthalmol. 1989;86(3):221-3
2759534
Am J Ophthalmol. 2006 Jul;142(1):1-9
16815245
Retina. 2006 Mar;26(3):275-8
16508426
Am J Ophthalmol. 1969 Oct;68(4):578-94
5394449
Retina. 2008 Jun;28(6):831-8
18536599
Retina. 2006 Mar;26(3):279-84
16508427
Graefes Arch Clin Exp Ophthalmol. 2008 Jul;246(7):1061-3
18320201